鶹ýӰ

1 in 5 Adults Report Anxiety, Depression; Esketamine Label Update; Autism Dx Up 175%

— News and commentary from the psychiatry world

by Kristen Monaco, Senior Staff Writer, MedPage Today

MedpageToday
Illustration of a brain shaped maze.

One in five adults said they of anxiety or depression in a 2-week period, according to a 2022 CDC survey.

The FDA updated a (Spravato) about the long-term cognitive and memory impairments that have been reported with ketamine misuse or abuse. New 3-year open-label trial data showed that the effect on cognitive functioning remained stable over time.

Ketamine was detected in in the U.S., a 2019-2023 analysis found. (Morbidity and Mortality Weekly Report)

Why did for bipolar disorder? (The Guardian)

Greater depression severity was and elevated HbA1c, fasting glucose, and insulin levels, an analysis of national survey data found. (Scientific Reports)

Over the past 50 years, the prevalence of and was tied to increased risks of relapse, psychiatric hospitalization, and worse global functioning versus monotherapy. (Lancet Psychiatry)

Investigational emraclidine , failing to reduce symptom severity in adults with schizophrenia who were experiencing an acute exacerbation of psychotic symptoms, said developer AbbVie.

College students in sexual and gender minority groups were more likely , a survey study showed. (Journal of American College Health)

increased 175% from 2011 to 2022, and are becoming more prevalent in young adults, according to a cross-sectional study. (JAMA Network Open)

A psychiatrist explains the difference between "normal" anxiety . (Washington Post)

Brief cognitive behavioral therapy by video telehealth with recent suicidal ideation or behavior in a randomized trial. (JAMA Network Open)

BioXcel said a phase III testing its investigational drug for agitation associated with bipolar disorders, schizophrenia, and Alzheimer's dementia is now underway.

The Canadian Research Initiative in Substance Matters released a guideline update for the , recommending buprenorphine and methadone as first-line treatments. (CMAJ)

Increasing persisted into 2022, a national cross-sectional study showed. (Annals of Internal Medicine)

Correction: A previous version of the story stated esketamine's label warning was new. The existing warning was updated.

  • author['full_name']

    Kristen Monaco is a senior staff writer, focusing on endocrinology, psychiatry, and nephrology news. Based out of the New York City office, she’s worked at the company since 2015.